Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis

PURPOSE: This study aims to determine the influence of targeting araC-resistant acute myeloid leukemia by dual inhibition cyclin-dependent protein kinase (CDK9) and B-cell lymphoma-2 （Bcl-2). METHOD: The c-Myc inhibitor 10058-F4 and the CDK9 inhibitor AZD4573 were used to determine the cell cycle ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Linzhang, Han, Chengwu, Yu, Xueying, Shen, Jun, Cao, Yongtong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808115/
https://www.ncbi.nlm.nih.gov/pubmed/35126914
http://dx.doi.org/10.1155/2022/2842066
_version_ 1784643817200156672
author Li, Linzhang
Han, Chengwu
Yu, Xueying
Shen, Jun
Cao, Yongtong
author_facet Li, Linzhang
Han, Chengwu
Yu, Xueying
Shen, Jun
Cao, Yongtong
author_sort Li, Linzhang
collection PubMed
description PURPOSE: This study aims to determine the influence of targeting araC-resistant acute myeloid leukemia by dual inhibition cyclin-dependent protein kinase (CDK9) and B-cell lymphoma-2 （Bcl-2). METHOD: The c-Myc inhibitor 10058-F4 and the CDK9 inhibitor AZD4573 were used to determine the cell cycle arrest and apoptosis. RESULTS: 10058-F4 reduces c-Myc protein levels and suppresses HepG2 cell proliferation, possibly by upregulating cyclin-dependent kinase (CDK) inhibitors, p21WAF1, and reducing intracellular alpha-fetal protein (AFP) levels. CONCLUSION: The combination of AZD4573 and 10058-F4 has a synergistic anti-araC-resistant AML activity, providing a solid database for the aforementioned scientific hypothesis.
format Online
Article
Text
id pubmed-8808115
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88081152022-02-03 Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis Li, Linzhang Han, Chengwu Yu, Xueying Shen, Jun Cao, Yongtong J Healthc Eng Research Article PURPOSE: This study aims to determine the influence of targeting araC-resistant acute myeloid leukemia by dual inhibition cyclin-dependent protein kinase (CDK9) and B-cell lymphoma-2 （Bcl-2). METHOD: The c-Myc inhibitor 10058-F4 and the CDK9 inhibitor AZD4573 were used to determine the cell cycle arrest and apoptosis. RESULTS: 10058-F4 reduces c-Myc protein levels and suppresses HepG2 cell proliferation, possibly by upregulating cyclin-dependent kinase (CDK) inhibitors, p21WAF1, and reducing intracellular alpha-fetal protein (AFP) levels. CONCLUSION: The combination of AZD4573 and 10058-F4 has a synergistic anti-araC-resistant AML activity, providing a solid database for the aforementioned scientific hypothesis. Hindawi 2022-01-25 /pmc/articles/PMC8808115/ /pubmed/35126914 http://dx.doi.org/10.1155/2022/2842066 Text en Copyright © 2022 Linzhang Li et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Linzhang
Han, Chengwu
Yu, Xueying
Shen, Jun
Cao, Yongtong
Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis
title Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis
title_full Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis
title_fullStr Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis
title_full_unstemmed Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis
title_short Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis
title_sort targeting arac-resistant acute myeloid leukemia by dual inhibition of cdk9 and bcl-2: a systematic review and meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808115/
https://www.ncbi.nlm.nih.gov/pubmed/35126914
http://dx.doi.org/10.1155/2022/2842066
work_keys_str_mv AT lilinzhang targetingaracresistantacutemyeloidleukemiabydualinhibitionofcdk9andbcl2asystematicreviewandmetaanalysis
AT hanchengwu targetingaracresistantacutemyeloidleukemiabydualinhibitionofcdk9andbcl2asystematicreviewandmetaanalysis
AT yuxueying targetingaracresistantacutemyeloidleukemiabydualinhibitionofcdk9andbcl2asystematicreviewandmetaanalysis
AT shenjun targetingaracresistantacutemyeloidleukemiabydualinhibitionofcdk9andbcl2asystematicreviewandmetaanalysis
AT caoyongtong targetingaracresistantacutemyeloidleukemiabydualinhibitionofcdk9andbcl2asystematicreviewandmetaanalysis

Ejemplares similares